Harvard Bioscience is a medical instruments & supplies business based in the US. Harvard Bioscience shares (HBIO) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $2.37 – a decrease of 2.87% over the previous week. Harvard Bioscience employs 391 staff and has a trailing 12-month revenue of around $101.1 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $2.37 |
|---|---|
| 52-week range | $2.32 - $5.56 |
| 50-day moving average | $2.77 |
| 200-day moving average | $3.60 |
| Wall St. target price | $6.25 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-0.25 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.47 from 2024-10-18
| 1 week (2024-10-16) | 1.23% |
|---|---|
| 1 month (2024-09-23) | -6.44% |
| 3 months (2024-07-23) | -25.15% |
| 6 months (2024-04-23) | -33.60% |
| 1 year (2023-10-23) | -41.19% |
|---|---|
| 2 years (2022-10-21) | 9.29% |
| 3 years (2021-10-22) | 6.96 |
| 5 years (2019-10-23) | 2.78 |
Valuing Harvard Bioscience stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Harvard Bioscience's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Harvard Bioscience's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.89. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Harvard Bioscience's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Harvard Bioscience's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $3.6 million.
The EBITDA is a measure of a Harvard Bioscience's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $101.1 million |
|---|---|
| Gross profit TTM | $62.3 million |
| Return on assets TTM | -1.62% |
| Return on equity TTM | -14.97% |
| Profit margin | -10.56% |
| Book value | $1.54 |
| Market Capitalization | $106.8 million |
TTM: trailing 12 months
We're not expecting Harvard Bioscience to pay a dividend over the next 12 months.
Harvard Bioscience's shares were split on a 1319:1000 basis on 3 November 2013 . So if you had owned 1000 shares the day before before the split, the next day you'd have owned 1319 shares. This wouldn't directly have changed the overall worth of your Harvard Bioscience shares – just the quantity. However, indirectly, the new 24.2% lower share price could have impacted the market appetite for Harvard Bioscience shares which in turn could have impacted Harvard Bioscience's share price.
Over the last 12 months, Harvard Bioscience's shares have ranged in value from as little as $2.32 up to $5.56. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Harvard Bioscience's is 1.292. This would suggest that Harvard Bioscience's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc.
Fundamental analysis of stocks can help you become a better investor and find the true value of stocks and other assets.
These are the stocks to buy when you don’t have much to spend.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
eToro is a robust trading platform with an easy-to-use interface and no commissions on stocks and ETFs.
Titan invest is a members-only automated platform best for hands-off investors looking to build wealth.
A beginner-friendly investing platform with fractional shares and no commissions on stocks and ETFs.
What you need to know about investing in the leading indicator for the overall US stock market.
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
Read our beginner’s guide to trading options in the US.